SCHEMBL2930191

SCHEMBL2930191

O=Cc1ccc(OCc2ccc(C(F)(F)F)cc2)c(C(=O)O)c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.54
RXRB P28702 1/20 0.54
RXRG P48443 1/20 0.54
KDM4E B2RXH2 1/20 0.54
ALDH1A1 P00352 1/20 0.54
POLB P06746 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
MRGPRX4 Q96LA9 5/20 0.54
FOLH1 Q04609 2/20 0.49
PTPN1 P18031 6/20 0.48
PTPN2 P17706 2/20 0.46
PTPN6 P29350 2/20 0.46
PTGER1 P34995 1/20 0.45
ALOX5 P09917 1/20 0.45
PSEN1 P49768 1/20 0.45
LRRK2 Q5S007 2/20 0.45
PPARD Q03181 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8847023 0.89 ALDH1A1 (0.64) KDM4EALDH1A1POLBL3MBTL1MRGPRX4
SCHEMBL2931922 0.89 RXRA (0.47) RXRARXRBRXRGKDM4EALDH1A1
SCHEMBL1647507 0.86 L3MBTL1 (0.57) KDM4EALDH1A1POLBL3MBTL1MRGPRX4
SCHEMBL8847033 0.84 FOLH1 (0.67) RXRARXRBRXRGKDM4EALDH1A1
SCHEMBL1648045 0.84 ALDH1A1 (0.73) KDM4EALDH1A1POLBL3MBTL1FOLH1
SCHEMBL23496317 0.83 PTPN1 (0.64) RXRARXRBRXRGALDH1A1PTPN1
SCHEMBL30002082 0.83 PTPN1 (0.64) RXRARXRBRXRGALDH1A1PTPN1
SCHEMBL8243758 0.83 LRRK2 (0.58) RXRARXRBRXRGMRGPRX4FOLH1
SCHEMBL5217355 0.82 TACR2 (0.54) RXRARXRBRXRGKDM4EALDH1A1
SCHEMBL856364 0.82 RXRA (0.59) RXRARXRBRXRGALDH1A1PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1313731-B1 THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT UCB SA (BE) 2010-09-29 EP disclosed
EP-1313731-B1 THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT UCB SA (BE) 2010-09-29 EP disclosed
US-6740670-B2 SUCH AS 5-(((3-(N-METHYL-N-PHENYLAMINO)CARBONYL-4-(PHENYL-METHOXY)) -PHENYL)METHYLENE)-4-OXO-2-THIOXO-3-THIAZOLIDINE-ACETIC ACID OXFORD GLYCOSCIENCES (UK) LTD. (GB) 2004-05-25 US disclosed
US-20030216453-A1 Thiazolidine derivatives and its use as antifungal agent OXFORD GLYCOSCIENCES (UK) LTD (GB) 2003-11-20 US disclosed
EP-1313731-A1 THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT Oxford GlycoSciences (UK) Limited (GB) 2003-05-28 EP disclosed
WO-2002022612-A1 THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT OXFORD GLYCOSCIENCES (UK) LIMITED (GB) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216453-A1 Thiazolidine derivatives and its use as antifungal agent CYP3A7, TAS2R7, OXSR1 RXRA 1171/4885RXRB 1398/4885RXRG 1236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.